Immunologic  Biomarkers for Clinical and Therapeutic Management of Psoriasis

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="236060.fig.005a" src="https://static.hindawi.com/articles/mi/volume-2014/236060/figures/236060.fig.005a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Etanercept</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="236060.fig.005b" src="https://static.hindawi.com/articles/mi/volume-2014/236060/figures/236060.fig.005b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Adalimumab</td></tr></table></td></tr><tr class="fig-image" id="c"><td><img alt="236060.fig.005c" src="https://static.hindawi.com/articles/mi/volume-2014/236060/figures/236060.fig.005c.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(c) </b>Infliximab</td></tr></table></td></tr></table>

<table>Analysis of lymphocyte subsets (T, B, NK lymphocytes, CD3+CLA+ and Treg cells) in peripheral blood of psoriasis patients before and during therapy with etanercept (a), adalimumab (b), and infliximab (c). Measurements were compared by one way ANOVA for repeated measures, nonparametric test. Depicted values are median and interquartile ranges.</table>

Mediators of Inflammation

fig5

Figure 5

Figure 5: Immunologic  Biomarkers for Clinical and Therapeutic Management of Psoriasis 